Explore Trades
All Companies

AMGN

Amgen Inc

Biological Products, (No Diagnostic Substances)

$385.65updated Sep 19, 2026

Congressional trading profile for Amgen Inc (AMGN), covering 36 disclosed transactions by 13 lawmakers.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Total Trades

36

Politicians Trading

13

Last Traded

Aug 26, 2026

Price history

Congressional Trades

PartyDemocratRepublican
ChamberHouseSenate
TypeBuySell
PoliticianNotifiedTradedTypeAmountChange
David TaylorRSep 5, 2026Aug 26, 2026Sell$1,001 - $15,000-12.42%
David TaylorRSep 5, 2026Aug 26, 2026Sell$1,001 - $15,000-12.42%
Sheldon WhitehouseDSep 2, 2026Aug 12, 2026Sell$1,001 - $15,000-7.34%
Ro KhannaDAug 7, 2026Jul 20, 2026Sell$1,001 - $15,000+5.90%
Ro KhannaDAug 7, 2026Jul 8, 2026Buy$1,001 - $15,000+4.80%
Alan ArmstrongRJul 21, 2026Mar 27, 2026Sell$15,001 - $50,000+10.57%
Ro KhannaDJul 6, 2026Jun 30, 2026Buy$1,001 - $15,000+6.50%
Ro KhannaDJul 6, 2026Jun 16, 2026Buy$1,001 - $15,000+10.87%
Ro KhannaDJul 6, 2026Jun 2, 2026Buy$1,001 - $15,000+17.48%
David TaylorRJun 12, 2026Jun 5, 2026Buy$1,001 - $15,000+10.32%
Ro KhannaDJun 9, 2026May 27, 2026Buy$15,001 - $50,000+14.76%
Ro KhannaDJun 9, 2026May 15, 2026Sell$15,001 - $50,000+18.19%
Ro KhannaDJun 9, 2026May 1, 2026Buy$15,001 - $50,000+16.93%
Ro KhannaDMay 11, 2026Apr 24, 2026Sell$15,001 - $50,000+11.93%
David TaylorRMar 6, 2026Feb 26, 2026Sell$1,001 - $15,000+1.67%
David TaylorRFeb 2, 2026Jan 29, 2026Sell$1,001 - $15,000+12.45%
David TaylorRFeb 2, 2026Jan 16, 2026Buy$1,001 - $15,000+16.72%
David TaylorRDec 5, 2025Dec 3, 2025Sell$1,001 - $15,000+11.65%
David TaylorRDec 5, 2025Dec 3, 2025Sell$1,001 - $15,000+11.65%
Marjorie Taylor GreeneROct 28, 2025Oct 24, 2025Buy$1,001 - $15,000+32.18%
Lisa C. McClainROct 22, 2025Sep 25, 2025Sell$1,001 - $15,000+42.21%
Sheldon WhitehouseDOct 3, 2025Sep 4, 2025Sell$1,001 - $15,000+37.68%
Marjorie Taylor GreeneRSep 27, 2025Sep 11, 2025Buy$1,001 - $15,000+36.40%
Daniel MeuserRAug 20, 2025Feb 11, 2025Sell$1,001 - $15,000+30.00%
Lisa C. McClainRAug 13, 2025Jun 24, 2025Buy$1,001 - $15,000+38.98%
Cliff BentzRJul 9, 2025Jun 6, 2025Buy$1,001 - $15,000+32.83%
Jefferson ShreveRJun 22, 2025May 12, 2025Sell$15,001 - $50,000+40.36%
Marjorie Taylor GreeneRMay 19, 2025May 14, 2025Buy$1,001 - $15,000+47.04%
Tommy TubervilleRMay 15, 2025Apr 15, 2025Sell$15,001 - $50,000+30.60%
Jared MoskowitzDMay 9, 2025Apr 16, 2025Buy$1,001 - $15,000+36.45%
Jared MoskowitzDMay 9, 2025Apr 16, 2025Buy$1,001 - $15,000+36.45%
Jefferson ShreveRMay 8, 2025Apr 11, 2025Buy$15,001 - $50,000+34.85%
Robert BresnahanRMay 8, 2025Apr 8, 2025Sell$1,001 - $15,000+37.60%
Marjorie Taylor GreeneRMay 6, 2025May 5, 2025Buy$1,001 - $15,000+37.70%
Jefferson ShreveRMar 9, 2025Feb 24, 2025Buy$15,001 - $50,000+24.52%
Emily RandallDFeb 11, 2025Jan 6, 2025Sell$1,001 - $15,000+49.14%